US FDA accepts for priority review Sanofi & Regeneron’s Dupixent sBLA for the targeted treatment of bullous pemphigoid: Paris Wednesday, February 19, 2025, 12:00 Hrs [IST] The U ...

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid <li /> If approved, Dupixent would be the ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

Natural treatments for lupus are often used alongside conventional medical treatment. They may be used to help reduce symptoms, which can include fatigue, joint pain, and hair loss. Lupus is an ...

The best flea treatments for cats are veterinarian-approved, safe, and effective, and often control other parasites like ticks, worms, and lice. I made my recommendations for this guide after ...

These findings provide a potential new, effective, disease-specific treatment option for lichen planus and therapeutic targets for other inflammatory diseases." Aaron R. Mangold, M.D., senior ...

Biopsy showed lichen simplex chronicus. There are no clinical manifestations ... Upper thighs, arm, and trunk responded extremely well after 10 treatments of UVB (about 1 month).

Nail biopsy: If lichen planus may be affecting one or more of your nails, your dermatologist will remove a small sample from the suspected area, so that it can be examined under a microscope. Not ...